Gwajin kwayar cutar kansa
Gwajin kwayoyin cutar kansa yana jagorantar maganin da aka yi niyya a matsayin ginshiƙan fasaha don ainihin maganin cutar kansa. Kowane mai ciwon daji ya kamata ya yi gwajin kwayar cutar kansa don kansa, yana neman ingantattun magungunan da aka yi niyya da gwajin asibiti don magani. Cibiyar sadarwa ta Global Oncologist Network, tare da hadin gwiwar hukumar gwajin kwayoyin halitta ta Amurka da hukumar gwajin kwayoyin halitta ta cikin gida, tana baiwa marasa lafiya sahihin gwajin kwayoyin cutar kansa da kuma ayyukan tuntubar kwararru don taimakawa marasa lafiya su tsara tsarin jiyya mafi inganci.
FDA kwanan nan ta amince da Iressa a matsayin wakili guda ɗaya don maganin ciwon huhu mara ƙananan ƙwayar cuta (NSCLC) tabbatacce ga maye gurbin mai karɓar haɓakar haɓakar epidermal (EGFR) wanda aka tabbatar ta hanyar kayan gwajin abokin FDA-yarda.
Iressa shine magani na farko da aka yi niyya da kwayoyin don maganin cutar kansar huhu a China. An kaddamar da shi a hukumance a kasar Sin tare da amincewar hukumar kula da ingancin abinci da magunguna ta kasar a shekarar 2005, inda ta bude wani sabon zamani na jiyya ga masu fama da cutar kansar huhu mara kanana. Iressa tana kawo ƙarin ingantattun zaɓuɓɓukan magani ga masu fama da cutar kansar huhu a China don inganta rayuwarsu kuma suna da ɗabi'ar tsawaita rayuwarsu. A bikin cika shekaru 6 na jerin sunayen Iressa, an kuma amince da Iressa a matsayin jiyya ta farko don cutar kansar huhun da ba ƙananan ƙwayoyin cuta ba.
Ciwon daji na huhu shine na daya a cikin adadin masu mutuwa da ke da alaƙa da ƙari a China. Ciwon daji na huhu mara ƙarami (NSCLC) ya kai kusan kashi 85% na duk cututtukan daji na huhu.
A halin yanzu, maganin ciwon huhu na huhu shine aikin tiyata, maganin radiation, da magungunan ƙwayoyi. Magungunan ƙwayoyi don ciwon huhu ya haɗa da chemotherapy da maganin ƙwayar cuta da aka yi niyya (na kowa zuwa EGFR-TKIs).
Maganin ciwon huhu na huhu, musamman ciwon huhu da ba ƙananan ƙwayoyin cuta ba, yana ba da shawarar tsarin kulawa na mutum ɗaya. Ya dogara ne akan yanayin bayyanar cututtukan huhu na masu cutar kansar huhu, wato, jiyya na mutum ɗaya dangane da ko masu ciwon huhu suna da kwayoyin halittar direba. Daga cikin su, mai karɓar haɓakar haɓakar haɓakar epidermal (EGFR) yana cikin mai karɓa na tyrosine kinase, kuma hanyar siginar siginar sa yana daidaita haɓakar tantanin halitta, haɓakawa da bambanta. A cikin ciwon daji, an gano cewa sauye-sauye daban-daban suna faruwa a cikin yankin EGFR tyrosine kinase. Wadannan maye gurbi suna da alaƙa da inganci na masu hana tyrosine kinase. Maye gurbin EGFR muhimmin direban ciwon daji ne. Maye gurbin EGFR shine ma'auni mai ƙarfi na ko masu ciwon daji suna kula da TKI. Don haka, gano maye gurbi na EGFR na iya samar da tushen jiyya da aka yi niyya. Adadin maye gurbin EGFR na masu cutar kansar huhu a China shine 30% -40%.
Shafukan maye gurbi na EGFR sun tantance ko marasa lafiya da ke fama da cutar kansar huhu na iya amfani da Iressa, Tarceva da sauran magungunan da aka yi niyya. Sauye-sauyen Iressa / Trokai a cikin exons 18, 19, 20, da 21, musamman shafe exon 19 ko maye gurbin exon 21, yana da tasiri mai mahimmanci. Ana ba da shawarar cewa marasa lafiya da ke fama da cutar kansar huhu mara ƙanƙanta su yi gwajin kwayoyin halitta kafin su yi amfani da magungunan da aka yi niyya kamar Iressa / Troca.
